ABSTRACT
globulin gene rearrangements is a hallmark of B-cell malignancy, and it is commonly manifested as restricted expression of immunoglobulin light chain RNA and protein (either k or l). 1 Clinical laboratory detection of immunoglobulin light chain restriction (LCR) is a helpful ancillary tool in the differential diagnosis that includes lymphoid hyperplasia, atypical lymphoid hyperplasia, chronic inflammation, and B-cell neoplasms. [2] [3] [4] [5] When fresh (unfixed) tissue is available for evaluation of lymphoma, the pathology laboratory processes a sample via a protocol that includes preparation of a cell suspension for flow cytometry (FCM) evaluation. LCR is readily detected as an abnormal k/l surface immunoglobulin ratio by this technique. However, not every laboratory has access to FCM, some B-cell lymphomas lack surface immunoglobulin expression detectable by FCM, others may demonstrate nonspecific antibody binding, and not all bone marrow aspirates and other specimens are evaluated by FCM. In referral centers, the pathologist reviewing the prior material in consultation typically has only formalin-fixed, paraffin embedded (FFPE) tissue available for evaluation. Furthermore, certain types of specimens limited in nature (eg, endoscopic biopsy specimens of extranodal sites) are typically presented for diagnosis without FCM results.
LCR identification by immunohistochemistry (IHC) and conventional chromogenic in situ hybridization (CISH) is feasible for B-cell neoplasms that express abundant k or l messenger RNA (mRNA) and cytoplasmic immunoglobulin protein. 6, 7 Plasma cell myeloma LCR is almost always feasible in FFPE tissue using these techniques, but only uncommon subsets of non-Hodgkin lymphoma (NHL) with abundant immunoglobulin mRNA and protein expression are evaluable by these traditional methods. Conversely, autoradiographic in situ hybridization (ISH) is sufficiently sensitive to detect the very low levels of light chain mRNA encountered in most NHL subtypes, including the most common NHL variants: follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), small B-cell lymphocytic lymphoma/chronic lymphocytic leukemia (CLL), nodal and splenic marginal zone lymphomas, mantle cell lymphoma, and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type. 8 But the time delay required for developing the autoradiographic signals and the inherent constraints on correlating message expression with the morphology of individual tumor cells have limited its clinical utility.
A recently developed novel bright-field ISH (BRISH) technology (RNAscope, Advanced Cell Diagnostics, Hayward, CA) enables single-RNA molecule sensitivity in FFPE specimens and is capable of multiplex detection in individual cells. [9] [10] [11] [12] [13] [14] [15] This approach represents a fundamental technological advance in molecular morphology and offers great promise for numerous applications in diagnostic pathology, especially those paraffin tissue section-based assays that require detection of very low levels of mRNA. BRISH enables sensitive detection of low-abundance mRNA in a cell-by-cell morphologic context.
We tested the hypothesis that delineation of immunoglobulin light chain clonal restriction in B-cell lymphomas of all types can be achieved with BRISH, including the common variants characterized by low levels of immunoglobulin light chain mRNA. A semiquantitative RNAscope-based CISH assay was developed to detect k/l mRNA expression in routinely fixed and processed tissue. Here we report the analytical performance of this assay in established cell lines in a semiconsecutive series of FFPE tissue submitted as part of a routine clinical lymphoma protocol based on FCM analysis of LCR and in a series of low-grade B-cell NHL in bone marrow and extranodal sites.
Materials and Methods

Cell Lines
Sixteen cell lines established from B-and T-cell lymphomas and leukemias were cultured at 37°C in 5% CO 2 ❚Table 1❚. The cell pellets at 200 to 300 × 10 6 cells per pellet were fixed in 10% neutral buffered formalin and embedded in paraffin. Supplemental FCM of fresh cells in suspension and/or IHC using 4-mm sections of the cell pellet cytoblocks were used to confirm T-or B-cell differentiation as required.
Case Selection
❚Table 2❚ summarizes the FFPE cases used for the study. Case selection was conducted following waiver of written informed consent and approval of the study by the Cleveland Clinic institutional review board. A semiconsecutive series of 110 FFPE tissues was assembled using the FCM records at our institution for patient tissue samples submitted for the lymphoma FCM panel. Cases were excluded if nonviable cell suspensions had been derived from the submitted tissue; CCL/ small lymphocytic lymphoma (SLL) cases were included only if sufficient surface immunoglobulin was present to determine the light chain phenotype by FCM. Subsequently, two separate additional cohorts were identified for further study: (1) a separate cohort of 20 paired bone marrow biopsy and clot sections 
Ultrasensitive BRISH
BRISH was performed using RNAscope as previously described, initially as single-color detection and subsequently as dual-color detection for both k and l mRNA on one slide ❚Figure 1❚. 14, 15 BRISH uses pairs of specially designed oligonucleotide probes (ZZ probes) that, via sequence-specific hybridization, recognize both the specific target RNA BRISH, bright-field in situ hybridization; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; LCR, light chain restriction; NOS, not otherwise specified; SIg, surface immunoglobulin detected by flow cytometry.
Target probe hybridization
Target probe pair Preampli er Ampli er Label probe ZZ…ZZ ❚Figure 1❚ Overview of duplex RNAscope (Advanced Cell Diagnostics, Hayward, CA) bright-field in situ hybridization assay for k and l messenger RNA light chain restriction.
Step 1: k-and l-specific ZZ probes (six pairs each) are hybridized together to a formalin-fixed, paraffin-embedded tissue section after pretreatment with heat and protease. Each pair of ZZ probes is designed to hybridize in tandem to the target RNA. Cross-hybridization to other sequences is minimized by screening against the entire human RNA sequence database.
Step 2: After hybridization with target RNA, each ZZ pair creates a 28-base binding site ("top side" of ZZ) for the signal preamplifier. The preamplifier, amplifier, and label probe are hybridized sequentially to assemble a tree-like complex at each ZZ binding site. Two independent sets of preamplifiers, amplifiers, and label probes are used to allow for dualcolor detection; one set contains horseradish peroxidase-conjugated label probe (large circles) and is recognized by k ZZ probes, and the other contains alkaline phosphatase-conjugated label probe (small circles) and is recognized by l ZZ probes. Nonspecific off-target binding by single Z probes will not result in signal amplification.
Step 3: l Signals are detected with Fast Red.
Step 4: k Signals are then detected with Deep Space Black.
sequence and a unique signal amplification system. Target probe oligonucleotides were designed by Advanced Cell Diagnostics (Hayward, CA) and manufactured by Eurofins MWG Operon (Huntsville, AL). The signal amplification system consists of the preamplifier, amplifier, and enzymeconjugated label probe, which assemble into a tree-like structure via sequential hybridization. Signal amplification occurs at target sites bound by ZZ probe pairs but not at off-target sites bound by single Z probes since a single Z probe contains only half (14 bases) of the preamplifier binding site (28 bases) and thus cannot bind stably to the preamplifier under the assay conditions. Multiplexing can be achieved by designing ZZ probes for multiple targets such that each target is coupled to a different signal amplification system. All steps of BRISH staining of the slides were performed manually. Briefly, FFPE unstained tissue sections (4 mm) were mounted on positively charged microscopic glass slides (Superfrost Plus, Thermo Fisher Scientific, Waltham, MA). Unstained paraffin sections were deparaffinized in xylene and rehydrated through a series of alcohols. The rehydrated sections were treated with 3% hydrogen peroxide at room temperature for 10 minutes to block endogenous peroxidase. Sections were then boiled in 1× citric buffer (10 nmol/L Nacitrate, pH 6.0) for 15 minutes and incubated with protease (2.5 mg/mL; Sigma Aldrich, St. Louis, MO) at 40°C for 30 minutes. The slides were hybridized sequentially with target probes (20 nmol/L) in hybridization buffer A (6× saline sodium citrate [SSC] buffer [1× SSC is 0.15 mol/L NaCl and 0.015 mol/L Na-citrate], 25% formamide, 0.2% lithium dodecyl sulfate [LDS] , and blocking reagents) at 40°C for 2 hours, signal preamplifier in hybridization buffer B (20% formamide, 5× SSC, 0.3% LDS, 10% dextran sulfate, and blocking reagents) at 40°C for 30 minutes, amplifier in hybridization buffer B at 40°C for 30 minutes, and horseradish peroxidase-or alkaline phosphatase-labeled probes in hybridization buffer C (5× SSC, 0.3% LDS, and blocking reagents) at 40°C for 15 minutes. In duplex assays, the target probes and signal amplifiers for the two targets were mixed and hybridized together at each step. Slides were washed in washing buffer (0.1× SSC) at room temperature after each hybridization step. Hybridization signals were detected as black and red colorimetric staining using Black and Fast Red chromogens, respectively (BioCare Biomedical, Concord, CA) followed by counterstaining with hematoxylin. Signals were granular and discrete black or red signals corresponding to individual mRNA targets.
Stained slides were scored qualitatively and semiquantitatively using conventional bright-field microscopy; an excess of one light chain mRNA species (ie, clonal restriction) was defined as either only signals of one light chain mRNA type or an excess of at least 5:1 signals for one light chain mRNA vs the alternate light chain. The BRISH preparations were reviewed by a hematopathologist (R.R.T.) blinded to the FCM results. Correlations with FCM results were then made, and a subset of the FCM series and the supplemental CLL/SLL bone marrow cases and the extranodal marginal zone lymphomas of MALT type were reviewed by a second hematopathologist (J.R.C.), who also assisted with discordance resolution.
In the final configuration of the assay, two consecutive unstained sections were dual stained (black k signals and red l signals) using probes for k and l mRNA (slide 1) and IGLL5 (red signals; see Discussion) and dapB (black signals; bacterial gene dapB serving as a negative control to assess background staining) (slide 2).
Target-specific probes were designed using custom software as described previously. 14 The GenBank accession numbers and probe regions are as follows: k (six ZZ pairs), JQ917465.1, 336 to 594; l (six ZZ pairs), HF541912.1, 333 to 612; IGLL5 (six ZZ pairs), NM_001178126.1, 7 to 448; and dapB (10 ZZ pairs), EF191515, 414 to 862.
Results
RNA ISH results for the series of cell lines derived from B-and T-cell lymphomas and leukemias are summarized in Table 1 . The B-cell cell lines were chosen specifically as having low levels of immunoglobulin mRNA undetectable by conventional ISH. The appropriate clonal LCR or absence of immunoglobulin light chain mRNA expression was observed, corresponding to the established phenotype for each cell line. Interestingly, FCM failed to detect any light chain expression in KARPAS 231, a cell line known to demonstrate l restriction, which was confirmed by BRISH (Table 1) . BRISH light chain restriction of FFPE from 27 plasma cell myelomas also matched the established phenotype. No cross-hybridization between k and l probes was observed in these cells highly expressing either k or l mRNA, demonstrating target specificity of the assay (data not shown).
The case mix encountered for the series of 110 biopsy tissues submitted per protocol for the FCM evaluation of lymphoma was representative of our practice at a large tertiary care center. Benign hyperplasias, FLs, and DLBCLs comprised most cases. RNA ISH results for the series are summarized in Table 2 The two supplemental B-cell lymphoproliferative disorder cohorts (CLL/SLL involving bone marrow and extranodal marginal zone lymphomas of MALT type) comprising two applications for which the assay may have especially valuable utility also provided data concordant with reference data sets. Results for conventional k and l IHC and CISH were uniformly negative or uninformative in the small lymphocytes. Plasma cells in one MALT case having a minor component of plasmacytic differentiation demonstrated k restriction with conventional CISH and IHC, but the involved lymphocytes were negative. Bone marrow biopsy specimens, rather than bone marrow clot sections, provided the most consistent results with BRISH since in most clot sections only the lymphocytes near the periphery of the clot demonstrated signals, likely attributable to poor fixative penetration of the clot. Even the light decalcification typically used for bone marrow biopsy specimens (decalcification solution D1209-1A [Cardinal Health, Dublin, OH], hydrochloric acid based, for 30 minutes followed by washing for 30 minutes in deionized water) did not compromise the detection of LCR, which was concordant in 18 of 20 cases In contrast to previously published approaches using autoradiographic ISH, BRISH enables both ultrasensitive single molecular mRNA detection within individual tumor cells and clinically acceptable resulting time (eight hours or overnight staining). 8, 14 The assay's strength will not be in replacing conventional CISH, which among B-cell malignancies can easily detect abundant light chain mRNA, or for that matter in conventional DLBCL, in which documenting LCR, although characteristic, is not an essential diagnostic requirement. 2, 16, 17 Rather, the assay's greatest utility will be in small B-lymphocyte infiltrates/proliferations where conventional IHC and CISH for assessing LCR are not useful. In some of these cases, especially limited endoscopic biopsy specimens, FCM results may not be available. In the latter class of specimens, apparent clonality identified by PCR using BIOMED-2 PCR or other derivative-based amplification strategies may represent pseudoclonality via amplification of DNA from a small number of B cells. 18, 19 In the early stages of development as we assessed feasibility, we encountered a major obstacle to the practical application of the assay: some of the B-cell lymphomas that were unequivocally clonally restricted by FCM demonstrated signals with both light chain probes. On careful inspection, the apparently spurious light chain signals were either exclusively nuclear or nuclear and restricted to a juxtanuclear region similar to the "Golgi zone" ❚Image 6❚. Furthermore, most
Discussion
For more than two decades, attempts have been made to develop a reliable CISH method for detecting immunoglobulin k/l mRNA for the assessment of B-cell clonality assessment in situ. Success has been achieved for some types of B-cell malignancies, and conventional k/l CISH is an important ancillary tool for use in the diagnosis of B-cell neoplasms with high levels of immunoglobulin light chain expression such as plasma cell myeloma, lymphoplasmacytoid lymphoma, plasmablastic variant of DLBCL, and those extranodal marginal zone lymphomas associated with plasma cell differentiation. 6 However, most NHLs that comprise the typical hematopathology practice-FL, DLBCL, CLL/ SLL, mantle cell lymphoma, splenic and marginal zone lymphoma, and extranodal marginal zone lymphoma of MALT type-express low levels of k/l mRNA and are typically not evaluable by conventional CISH. IHC for LCR in FFPE typically demonstrates very high background staining and either uninformative or ambiguous staining results for SLL/CLL, FL, most cases of DLBCL, and MALT not associated with plasmacytic differentiation.
Here we have demonstrated the utility of a novel, ultrasensitive bright-field nonradioactive ISH assay capable of reliable detection of immunoglobulin k/l mRNA restriction in common NHL variants expressing very low levels of light chain mRNA in routine fixed and processed FFPE. cases displaying this unexpected hybridization pattern were DLBCL in the series of 110 cases. The aberrant staining to ZZ probe hybridization to the genomic DNA target was initially attributed to the gene rather than the mRNA. However, when RNase pretreatment abrogated the unexpected staining pattern, other explanations were investigated. Probe hybridization to IGLL5 (immunoglobulin l-like polypeptide 5) mRNA sequences was ultimately identified as responsible for the aberrant staining. IGLL5 is located within the immunoglobulin l locus (22q11. and a biclonal DLBCL), cells with both k and l intranuclear signals were observed, but in each instance, the process was overtly clonally restricted. We did not encounter Burkitt or pre-B-lymphoblastic lymphoma/leukemia in our semiconsecutive series. Follow-up studies specifically focused on B-cell maturation stages and the potential usefulness of IGLL5 in stratifying DLBCL are planned. The final configuration of the assay includes two probe pairs: slide 1, including target probes for k and l mRNA ❚Image 6❚ Nuclear and globular cytoplasmic signals (brown) reminiscent of a Golgi zone staining pattern identified with a l probe in a k-restricted diffuse large B-cell lymphoma. Single-color bright-field in situ hybridization, diaminobenzidine detection, with hematoxylin counterstain (×200).
❚Image 7❚ IGLL5 gene structure. IGLL5 is located within the immunoglobulin l locus (22q11.22) but does not require somatic rearrangement for expression. The first exon of IGLL5 is unrelated to the immunoglobulin variable genes, but the second and third IGLL5 exons share the sequence of the immunoglobulin l joining 1 and the constant 1 gene segments (arrow).
❚Image 8❚ Follicular lymphoma, World Health Organization grade 3A, demonstrating occasional large cells with numerous intranuclear signals for both light chains. Only two cases demonstrated this particular pattern, and both were otherwise overtly light chain restricted. Dual-color bright-field in situ hybridization with hematoxylin counterstain (×1,000).
(black k signals and red l signals), and slide 2, including target probes for IGLL5 (red signals) and dapB (black signals; bacterial gene dapB serving as a negative control to assess background staining). The slide pair is best used algorithmically ❚Figure 2❚. 22 From a practical application point of view, codetection of light chain and IGLL5 message may not present a significant interpretative challenge; the assay will likely not be used in the diagnosis of DLBCL since the cells in question are clearly neoplastic by morphology, and other IHC and molecular markers used to subtype DLBCL work well in FFPE tissues. The assay will have its greatest utility in other types of lymphomas, primarily low-grade NHL. However, when k-restricted large B-cell lymphomas are probed by BRISH, red intranuclear signals will be identified by both the l and IGLL5 ZZ probes. ❚Image 9❚ illustrates this pattern in a case of T-cell/histiocyte-rich large B-cell lymphoma.
In the semiconsecutive series of cases reported here, only a few T-cell NHL and classic Hodgkin lymphoma (CHL) cases were encountered, representative of the case mix at our institution and regional health system practice. Cases of T-cell NHL were consistently negative for mRNA expression. Hodgkin cells of CHL were negative or demonstrated only a rare single nuclear mRNA copy or either light chain type, observations consistent with published evidence that the Hodgkin cells are derived from preapoptotic germinal center B cells carrying rearranged and somatically mutated immunoglobulin V genes that are nonproductive of immunoglobulin. [23] [24] [25] [26] [27] [28] [29] In summary, here we have tested the hypothesis that ultrasensitive mRNA ISH enables reliable detection of clonally restricted immunoglobulin light chain mRNA expression and demonstrated the concordance of this robust approach with conventional immunophenotyping by FCM. The same caveats apply to the interpretation of the results for this approach as for any ancillary technique in hematopathology: B-cell clonality does not necessarily equate to malignant lymphoma. 2, 18, 19, 30, 31 Detection of LCR using the approach outlined here will have its greatest utility in low-grade B-cell-rich infiltrates in bone marrow and extranodal sites in clinical scenarios in which fresh tissue is not available for FCM or morphologic correlates in situ are necessary. Future studies using the approach presented here could address the use of the assay in a prospective manner paired with FCM, in the differential diagnosis of CHL vs primary mediastinal large B-cell lymphoma and lymphomas κ-/λ-❚Figure 2❚ Interpretative algorithm to account for detection of IGLL5 sequences with a l light chain probe in B-cell lymphoma of early B-cell differentiation. Individual tumor cells are examined for k and l messenger RNA expression and colocalization on a dual-color slide. Hodgkin and T-cell lymphoma cells are negative for both k and l. Expression of only k (black) or l (red) indicates k or l light chain restriction. When both k and l signals are present in the same cell, the signal level of the l probe is compared with that of IGLL5 on a separate slide costained for IGLL5 (red) and dapB (black). If the number of punctate IGLL5 signal dots is at least similar to that of the l probe signals, it indicates that the l probe signals are most likely from IGLL5, thus consistent with k restriction. In some rare cases, the number of IGLL5 signal dots is much less than that of the l probe signals, indicating l origin of the l probe signals and thus k and l coexpression in the same cell. This nonrestricted (NR) or biallelic light chain expression pattern has been reported in flow cytometry studies. 22 
